⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL435100 | 0.76 | — | — | |
| SCHEMBL17366415 | 0.75 | ALDH1A1 (0.50) | — | |
| SCHEMBL29574715 | 0.75 | ALDH1A1 (0.50) | — | |
| SCHEMBL16289359 | 0.75 | — | — | |
| SCHEMBL29440483 | 0.73 | ALDH1A1 (0.48) | — | |
| SCHEMBL5789919 | 0.73 | ALDH1A1 (0.48) | — | |
| SCHEMBL24377494 | 0.73 | CNR2 (0.45) | — | |
| SCHEMBL1604458 | 0.73 | KMT2A (0.52) | — | |
| SCHEMBL3662562 | 0.73 | ALDH1A1 (0.42) | — | |
| SCHEMBL1604461 | 0.73 | KMT2A (0.52) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4619404-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | Prelude Therapeutics Incorporated (US) | 2025-09-24 | — | — | EP | disclosed |
| EP-4587127-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | Prelude Therapeutics Incorporated (US) | 2025-07-23 | — | — | EP | disclosed |
| US-20240190886-A1 | BRM Targeting Compounds and Associated Methods of Use | PRELUDE THERAPEUTICS INCORPORATED | 2024-06-13 | — | — | US | disclosed |
| WO-2024107711-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | PRELUDE THERAPEUTICS INCORPORATED (US) | 2024-05-23 | — | — | WO | disclosed |
| US-20240165244-A1 | BRM Targeting Compounds And Associated Methods Of Use | PRELUDE THERAPEUTICS INCORPORATED | 2024-05-23 | — | — | US | disclosed |
| WO-2024059806-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | PRELUDE THERAPEUTICS INCORPORATED (US) | 2024-03-21 | — | — | WO | disclosed |
| US-11186588-B2 | 6H-thieno[2,3-e][1,2,4]triazolo[3,4-c][1,2,4]triazepine derivative | AYUMI PHARMACEUTICAL CORPORATION (JP) | 2021-11-30 | — | — | US | disclosed |
| US-11141495-B2 | MRI imaging of amyloid plaque using liposomes | TEXAS CHILDREN'S HOSPITAL (US) | 2021-10-12 | — | — | US | disclosed |
| US-20210130367-A1 | 6H-THIENO[2,3-e][1,2,4]TRIAZOLO[3,4-c][1,2,4]TRIAZEPINE DERIVATIVE | AYUMI PHARMACEUTICAL CORPORATION (JP) | 2021-05-06 | — | — | US | disclosed |
| US-20200179540-A1 | MRI IMAGING OF AMYLOID PLAQUE USING LIPOSOMES | TEXAS CHILDREN'S HOSPITAL | 2020-06-11 | — | — | US | disclosed |
| EP-3204051-B1 | MRI IMAGING OF AMYLOID PLAQUE USING LIPOSOMES | Texas Childrens Hospital (US) | 2019-05-29 | — | — | EP | disclosed |
| US-20170080111-A1 | MRI IMAGING OF AMYLOID PLAQUE USING LIPOSOMES | Alzeca Biosciences, LLC | 2017-03-23 | — | — | US | disclosed |